Chronic Lymphocytic Leukemia — A Study of ABT-263 in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia
Citation(s)
A Phase 1/2a Study Evaluating the Safety, Pharmacokinetics, and Efficacy of ABT-263 in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia